So, Ryuhei
Furukawa, Toshi A.
Matsushita, Sachio
Baba, Toshiaki
Matsuzaki, Takanobu
Furuno, Satoshi
Okada, Hitomi
Higuchi, Susumu
Funding for this research was provided by:
Japan Agency for Medical Research and Development
Article History
First Online: 11 March 2020
Compliance with Ethical Standards
:
: RS, SM, TM, SF, HO, and SH had been involved in the development of the workbook for face-to-face group CBT for Gambling Disorder on which the content of GAMBOT was based. GAMBOT was mainly developed by RS referring to the workbook. Both the workbook and GAMBOT were developed not for business but for academic interest. RS has received personal fees from Igaku-shoin Co., Ltd., Kagaku-hyoronsha Co., Ltd., Medical Review Co., Ltd., Otsuka Pharmaceutical Co., Ltd., and CureApp Inc. outside the submitted work. TAF reports personal fees from Meiji, grants and personal fees from Mitsubishi-Tanabe, personal fees from MSD, personal fees from Pfizer, outside the submitted work; TAF has a patent 2018-177688 pending. SH, TM, SF, HO, and TB declared no conflict of interest. The authors have received national funding from the Japan Agency for Medical Research and Development (AMED).